title: Plain radiography or magnetic resonance imaging (MRI): Which is better in assessing outcome in clinical trials of disease-modifying osteoarthritis drugs? Summary of a debate held at the World Congress of Osteoarthritis 2014.
abstract: Osteoarthritis (OA) is the most common disease of synovial joints and currently lacks treatment options that modify structural pathology. Imaging is ideally suited for directly evaluating efficacy of disease-modifying OA drugs (DMOADs) in clinical trials, with plain radiography and MRI being most often applied. The current article is based on a debate held on April 26, 2014, at the World Congress of Osteoarthritis: The authors were invited to contrast strengths and limitations of both methods, highlighting scientific evidence on reliability, construct-validity, and correlations with clinical outcome, and comparing their sensitivity to change in knee OA and sensitivity to DMOAD treatment. The authors concluded that MRI provides more comprehensive information on articular tissues pathology, and that implementation of radiography in clinical trials remains a challenge. However, neither technique has thus far been demonstrated to be strongly superior over the other; for the time being it therefore appears advisable to use both in parallel in clinical trials, to provide more evidence on their relative performance. Radiographic JSW strongly depends on adequate positioning; it is not specific to cartilage loss but also to the meniscus. MRI provides somewhat superior sensitivity to change compared with the commonly used non-fluoroscopic radiographic acquisition protocols, and has recently provided non-location-dependent measures of cartilage thickness loss and gain, which are potentially more sensitive in detecting DMOAD effects than radiographic JSW or region-specific MRI. Non-location-dependent measures of cartilage thickness change should thus be explored further in context of anabolic and anti-catabolic DMOADs.
authors.affiliation: Institute of Anatomy, Paracelsus Medical University Salzburg & Nuremberg, Strubergasse 21, A5020 Salzburg, Austria; Chondrometrics GmbH, Ainring, Germany. Electronic address: felix.eckstein@pmu.ac.at.
authors.forename: Felix
authors.initials: F
authors.lastname: Eckstein
authors.affiliation: Pfizer Global Medicines Development, Global Innovative Products Business, New York, NY.
authors.forename: Marie-Pierre Hellio
authors.initials: MP
authors.lastname: Le Graverand
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D002358:Cartilage, Articular / Q000000981:diagnostic imaging / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D010003:Osteoarthritis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D017063:Outcome Assessment, Health Care / Q000379:methods*; D011859:Radiography; D015203:Reproducibility of Results; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents
keywords: Cartilage thickness; Joint space width (JSW); Magnetic resonance imaging (MRI); Osteoarthritis–clinical trial–disease-modifying OA drugs (DMOADs); Radiography